197 related articles for article (PubMed ID: 8167558)
1. Soluble interleukin-2 receptor levels in cytomegalovirus disease and graft versus host disease after T-lymphocyte depleted bone marrow transplantation for hematological neoplasias.
Engelhard D; Nagler A; Singer R; Barak V
Leuk Lymphoma; 1994 Jan; 12(3-4):273-80. PubMed ID: 8167558
[TBL] [Abstract][Full Text] [Related]
2. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogenic bone marrow transplantation.
Foley R; Couban S; Walker I; Greene K; Chen CS; Messner H; Gauldie J
Bone Marrow Transplant; 1998 Apr; 21(8):769-73. PubMed ID: 9603399
[TBL] [Abstract][Full Text] [Related]
3. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease.
Miyamoto T; Akashi K; Hayashi S; Gondo H; Murakawa M; Tanimoto K; Harada M; Niho Y
Bone Marrow Transplant; 1996 Feb; 17(2):185-90. PubMed ID: 8640164
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of serum soluble interleukin-2 receptor levels in acute and chronic graft-versus-host disease.
Kobayashi S; Imamura M; Hashino S; Tanaka J; Asaka M
Leuk Lymphoma; 1997 Dec; 28(1-2):159-69. PubMed ID: 9498715
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of soluble interleukin-2 receptor after bone marrow transplantation: a true marker of acute graft-versus-host disease.
Kami M; Matsumura T; Tanaka Y; Mikami Y; Miyakoshi S; Ueyama J; Morinaga S; Mori S; Machida U; Kanda Y; Chiba S; Sakamaki H; Hirai H; Muto Y
Leuk Lymphoma; 2000 Aug; 38(5-6):533-40. PubMed ID: 10953974
[TBL] [Abstract][Full Text] [Related]
6. Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantations as a marker for GVHD.
Grimm J; Zeller W; Zander AR
Bone Marrow Transplant; 1998 Jan; 21(1):29-32. PubMed ID: 9486491
[TBL] [Abstract][Full Text] [Related]
7. Serum cytokine levels after HLA-identical bone marrow transplantation.
Liem LM; van Houwelingen HC; Goulmy E
Transplantation; 1998 Oct; 66(7):863-71. PubMed ID: 9798695
[TBL] [Abstract][Full Text] [Related]
8. Increased levels of soluble interleukin-2 receptor in veno-occlusive disease of the liver after allogenic bone marrow transplantation.
Remberger M; Ringdén O
Transplantation; 1995 Dec; 60(11):1293-9. PubMed ID: 8525524
[TBL] [Abstract][Full Text] [Related]
9. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients.
Shaiegan M; Iravani M; Babaee GR; Ghavamzadeh A
Transpl Immunol; 2006 Jan; 15(3):223-7. PubMed ID: 16431290
[TBL] [Abstract][Full Text] [Related]
10. Soluble interleukin-6 receptors in hematology patients undergoing bone marrow transplantation.
Toren A; Novick D; Or R; Ackerstein A; Slavin S; Nagler A
Transplantation; 1996 Jul; 62(1):138-42. PubMed ID: 8693533
[TBL] [Abstract][Full Text] [Related]
11. Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation.
Soiffer RJ; Gonin R; Murray C; Robertson MJ; Cochran K; Chartier S; Cameron C; Daley J; Levine H; Nadler LM
Blood; 1993 Oct; 82(7):2216-23. PubMed ID: 7691252
[TBL] [Abstract][Full Text] [Related]
12. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
[TBL] [Abstract][Full Text] [Related]
13. Soluble interleukin-2 receptor level on day 7 as a predictor of graft-versus-host disease after HLA-haploidentical stem cell transplantation using reduced-intensity conditioning.
Kaida K; Ikegame K; Ikemoto J; Murata R; Irie R; Yoshihara S; Ishii S; Okada M; Inoue T; Tamaki H; Soma T; Fujimori Y; Kai S; Ogawa H
Int J Hematol; 2014 Apr; 99(4):463-70. PubMed ID: 24599414
[TBL] [Abstract][Full Text] [Related]
14. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
15. Soluble interferon-gamma receptor and interferon-gamma in patients undergoing allogeneic bone marrow transplantation for hematological malignancies.
Toren A; Barak V; Novick D; Nagler A
Cytokines Cell Mol Ther; 1997 Sep; 3(3):153-8. PubMed ID: 9426973
[TBL] [Abstract][Full Text] [Related]
16. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus pneumonia prior to engraftment following T-cell depleted bone marrow transplantation.
Nagler A; Elishoov H; Kapelushnik Y; Breuer R; Or R; Engelhard D
Med Oncol; 1994; 11(3-4):127-32. PubMed ID: 7633832
[TBL] [Abstract][Full Text] [Related]
18. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
[TBL] [Abstract][Full Text] [Related]
19. Soluble interleukin-2 receptor index predicts the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors.
Nakamura Y; Tanaka Y; Tanaka M; Sugiyama A; Yamamoto K; Tokunaga Y; Yujiri T; Tanizawa Y
Int J Hematol; 2016 Apr; 103(4):436-43. PubMed ID: 26791380
[TBL] [Abstract][Full Text] [Related]
20. Ganciclovir for the treatment of disseminated CMV disease without pneumonia in allogeneic T-lymphocyte depleted bone marrow transplantation.
Engelhard D; Naparstek E; Or R; Nagler A; Jacobs J; Shahar MB; Hardan I; Baciu H; Raveh D; Slavin S
Leuk Lymphoma; 1993 May; 10(1-2):143-6. PubMed ID: 8397030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
